Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients-Reference-Cited by-同舟云学术

Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients

Published:2013-08 Issue:7 Volume:62 Page:577-583
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Erlinge David,Gurbel Paul A.,James Stefan,Lindahl Tomas L.,Svensson Peter,Ten Berg Jurrien M.,Foley David P.,Wagner Henrik,Brown Patricia B.,Luo Junxiang,Zhou Chunmei,Moser Brian A.,Jakubowski Joseph A.,Small David S.,Winters Kenneth J.,Angiolillo Dominick J.

Funder

Daiichi Sankyo Company Ltd.

Eli Lilly and Company

AstraZeneca, Daiichi Sankyo Company, Ltd., Eli Lilly and Co., Pozen, Bayer Healthcare, Sanofi-Aventis, CSL Pharmaceuticals, Accumetrics, Nanosphere, and Haemoscope

AstraZeneca, Eli Lilly and Co., Merck, and Bristol-Myers Squibb

Accumetrics, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo Company, Ltd., Eli Lilly and Co., Eisai, GlaxoSmithKline, Otsuka, Portola, Sanofi-Aventis, Schering-Plough, and The Medicines Company

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference12 articles.

1. Prasugrel versus clopidogrel in patients with acute coronary syndromes;Wiviott;N Engl J Med,2007

2. Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy;Riesmeyer;J Clin Pharmacol,2012

3. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38;Wrishko;J Clin Pharmacol,2009

4. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER Trial;Erlinge;J Am Coll Cardiol,2012

5. Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial;Small;Drugs Aging,2009

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiplatelet Effect of Low-Dose Prasugrel in Elderly Patients Undergoing Percutaneous Coronary Interventions;Current Vascular Pharmacology;2024-09

2. Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes;International Journal of Molecular Sciences;2024-04-03

3. Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome;Journal of Thrombosis and Thrombolysis;2024-03-31

4. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines;Circulation;2023-08-29

5. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease;Journal of the American College of Cardiology;2023-08